Acute Kidney Injury in Upper GI Bleeding Patients
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSohag University
About this trial
This study aims to evaluate the incidence of acute kidney injury (AKI) among patients presenting with acute upper gastrointestinal bleeding (UGIB) at Sohag University Hospitals, and to identify predictors associated with renal impairment in these patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult patients aged 18 years or older
Patients presenting with clinical features suggestive of acute upper gastrointestinal bleeding (UGIB), including hematemesis, coffee-ground vomiting, or melena
Diagnosis of UGIB confirmed by upper gastrointestinal endoscopy or strong clinical evidence when endoscopy is not immediately available
Patients admitted to Sohag University Hospitals (medical wards or intensive care unit)
Disqualifiers
Patients with end-stage renal disease (ESRD) on chronic dialysis
Patients with a history of renal transplantation
Patients with advanced chronic kidney disease stage 5 (eGFR <15 mL/min/1.73 m²) not on dialysis
Patients with lower gastrointestinal bleeding
Trial population
Adult patients presenting with acute upper gastrointestinal bleeding and admitted to Sohag University Hospitals, including both ward and ICU patients, who meet the eligibility criteria and have available renal function data.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Observational assessment
Other interventionNo therapeutic intervention is applied. Patients are managed according to standard hospital care, and data are collected observationally.
Treatment groups
200 Participants
are divided into 1 treatment groupGroup A: Patients with Acute Upper Gastrointestinal Bleeding1 intervention
Trial outcomes
Primary outcomes
1
Incidence of Acute Kidney Injury (AKI) According to KDIGO Criteria
The incidence of acute kidney injury (AKI) among patients presenting with acute upper gastrointestinal bleeding (UGIB), defined according to KDIGO criteria based on changes in serum creatinine and/or urine output during hospitalization.
Time frame
From hospital admission through hospital discharge, up to 30 daysSecondary outcomes
1
Percentage of Patients Developing AKI According to Bleeding Etiology
Comparison of AKI incidence between variceal and non-variceal UGIB patients.
Time frame
Baseline (hospital admission) with AKI occurrence assessed through hospital discharge, up to 30 days2
Change in Serum Creatinine Concentration
Serum creatinine concentration (mg/dL) measured at admission and during hospitalization to assess changes in renal function.
Time frame
Through hospital discharge, up to 30 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: